Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
Conditions
Keywords
Claudin-1 Targeted Antibody-Drug Conjugate, Monotherapy, First-in-Human, Recommended Phase 2 dose, Recommended dose for expansion
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
Detailed description
This Study has a Phase I ALE.P02 monotherapy dose escalation and recommended dose for expansion (RDE) study and a Phase II study of ALE.P02 as monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.
Interventions
DRUGALE.P02
ALE.P02, will be administered by IV infusion according to the assigned arms.
Sponsors
Alentis Therapeutics AG
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have disease and treatment history as: Have histologically or cytologically confirmed advanced locally recurrent and inoperable or metastatic SqNSCLC, HNSCC (nasopharyngeal cancer included), ESCC or CSCC. * Phase I Dose Escalation: Have received at least one systemic standard of care regimen and being refractory or intolerant to the treatment. * Phase I RDE and Phase II: Have received no more than 2 lines of systemic standard of care regimen and being refractory or intolerant to the treatment. * Have provided tissue for CLDN1 analysis in a central laboratory. * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale. * Demonstrate adequate bone marrow and organ function. * Patients must have recovered from all toxicities led by prior treatment. * Have measurable disease based on RECIST 1.1 as determined by the site.
Exclusion criteria
* Diagnosed with cancers of predominantly non-squamous histology (eg, adenosquamous carcinoma) or adenocarcinoma. * Has received antineoplastic therapies prior to study intervention within specified time frame. * Has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain). * Patients with uncontrolled diabetes. * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has clinically significant gastrointestinal bleeding and has an active infection requiring systemic treatment and has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study, interfere with the patient's participation for the full duration of the clinical study, or is not in the best interest of the patient to participate. * Concomitant use of drugs that are known to prolong or shorten QT and/or have known risk of Torsades de Pointes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients with Dose Limiting Toxicities (DLTs) | Up to 28 days | DLTs as defines in the protocol will be assessed to evaluate safety and tolerability of ALE.P02 (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE). |
| Number of Patients with Adverse Events | Screening (day -28 to day -1) up to Safety follow-up (30 ± 5 days post last dose [Up to 3.5 years]) | Adverse events will be assessed to evaluate safety and tolerability of ALE.P02 (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE). |
| Overall Response Rate (ORR) (Phase I) | From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years) | The ORR is the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) This is assessed to establish RP2D for ALE.P02 (Phase I RDE) |
| Duration of Response (DoR) (Phase I) | From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years) | The DoR is defined for patients achieving a confirmed CR or PR as the time from the initial response of CR or PR per Investigator review according to RECIST 1.1 to disease progression or death of any cause, whichever occurs earlier. This is assessed to establish RP2D for ALE.P02 (Phase I RDE). |
| Overall Response Rate (ORR) (Phase II) | From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years) | The ORR is assessed to assess anti-tumor activity of ALE.P02 (Phase II). |
| Duration of Response (DoR) (Phase II) | From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years) | The DoR is assessed to assess anti-tumor activity of ALE.P02 (Phase II). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) (Phase I and II) | From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years) | The DCR is defined as the proportion of patients with a confirmed BOR of CR or PR or stable disease (SD) per Investigator review according to RECIST 1.1 at or prior to initiation of the use of new anti-cancer therapy. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II). |
| Median Progression-Free Survival (PFS) at 6 and 12 Months (Phase I and II) | At 6 and 12 months after initiation of ALE.P02 treatment | The PFS is defined as time from first study treatment to a documented disease progression according to RECIST 1.1, as determined by the Investigator, or death due to any cause, whichever occurs earlier. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II). |
| Median Overall Survival (OS) at 6, 12, and 24 Months (Phase I and II) | At 6, 12, and 24 months after initiation of ALE.P02 treatment | The OS is defined as time from first study treatment to death due to any cause. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II). |
| Blood Concentration of ALE.P02 Antibody-drug Conjugate (ADC) | Phase I and II: Cycle 1 Day 1 until at end of treatment visit (EoT) (Up to 3.5 years) | Concentrations of ALE.P02 ADC in blood will be measured at each scheduled time point per arms to assess the pharmacokinetic (PK) profile of ALE.P02. |
| Blood Concentration of Total Antibody | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | Total antibody in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02. |
| Blood Concentrations of Payload | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | Concentrations of payload in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02. |
| Area under the concentration-time curve over the dosing interval (AUCtau) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The AUCtau of ALE.P02 will be measured to assess the pharmacokinetic (PK) profile of ALE.P02. |
| Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The AUClast of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The AUCinf of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| Maximum Concentration (Cmax) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The Cmax of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile. |
| Minimum concentration (Cmin) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The Cmin of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile. |
| Concentration at the end of a Dosing Interval (Ctrough) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The Ctrough of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| The terminal elimination rate constant (KeL) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The KeL of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined by selection of at least three data points on the terminal phase of the concentration-time curve. |
| Terminal elimination half-life (t½) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The t½ of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| Time of Maximum Concentration (tmax) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The tmax of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| Average Concentration (Cavg) | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | The Cavg of ALE.P02 will be measured to assess the PK profile of ALE.P02. |
| Number of Patients with Presence of anti-ALE.P02 Antibodies | Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years) | Presence of anti-ALE.P02 Antibodies will be assessed to evaluate the immunogenicity of ALE.P02. |
Countries
France, Hong Kong, Italy, Singapore, South Korea, Spain, Taiwan, United States
Contacts
CONTACTAlentis Clinical Trial Contact
Outcome results
None listed